US EditionBioNTech to Pay CureVac, GSK $740M Plus Royalties to Settle mRNA Patent Disputes
GERMANY, AUG 8 – BioNTech will pay up to $870 million plus royalties to CureVac and GSK to resolve patent claims and focus on its mRNA vaccine programs, with royalties starting in 2025.
- On Friday, BioNTech said it will pay CureVac and GSK, with GSK said to receive $320 million from CureVac, ending the patent dispute ahead of its CureVac acquisition.
- After emerging as an early COVID-19 vaccine contender in 2020, CureVac agreed to a $370 million settlement with GSK, unrelated to any lawsuit against BioNTech.
- Financial breakdown shows CureVac will receive a $370 million payout and 1% royalties, while BioNTech will pay GSK $370 million upfront and $130 million at acquisition.
- BioNTech said settling allows it to focus on strategy and grants a non-exclusive U.S. license for mRNA COVID-19 and influenza vaccines.
- In Europe, the European Patent Office upheld two CureVac patents, setting the stage for a Dusseldorf trial, while BioNTech’s $1.25 billion acquisition is expected to close by the end of 2025.
18 Articles
18 Articles
BioNTech to Pay CureVac, GSK $740M Plus Royalties to Settle mRNA Patent Disputes
The deal helps move BioNTech’s proposed acquisition of CureVac closer to completion. With the settlement, GSK said it will tender the CureVac shares it owns in support of the $1.25 billion acquisition. The post BioNTech to Pay CureVac, GSK $740M Plus Royalties to Settle mRNA Patent Disputes appeared first on MedCity News.
Recently, the two companies announced surprisingly that they would join forces. In the course of this, a conflict that had been simmering for years has now been resolved, with a million-dollar payment.
A few weeks ago it became known that Biontech wanted to take over the German competitor. Now an obstacle was removed on the way there.
A few weeks ago it became known that Biontech wanted to take over the German competitor. Now an obstacle was removed on the way there.
Coverage Details
Bias Distribution
- 83% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
